Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study

Andrew J. Stewardson, Kalisvar Marimuthu, Sharmila Sengupta, Arthur Allignol, Maisra El-Bouseary, Maria J. Carvalho, Brekhna Hassan, Monica A. Delgado-Ramirez, Anita Arora, Ruchika Bagga, Alex K. Owusu-Ofori, Joseph O. Ovosi, Shamsudin Aliyu, Hala Saad, Souha S. Kanj, Basudha Khanal, Balkrishna Bhattarai, Samir K. Saha, Jamal Uddin, Purabi BarmanLatika Sharma, Tarek El-Banna, Rabaab Zahra, Mansab Ali Saleemi, Amarjeet Kaur, Kenneth Iregbu, Nkolika SC Uwaezuoke, Pierre Abi Hanna, Rita Feghali, Ana L. Correa, Maria I. Munera, Thi Anh Thu Le, Thi Thanh Nga Tran, Chimanjita Phukan, Chiranjita Phukan, Sandra L. Valderrama-Beltrán, Carlos Alvarez-Moreno, Timothy R. Walsh, Stephan Harbarth

Research output: Contribution to journalArticleResearchpeer-review

32 Citations (Scopus)


Background: Low-income and middle-income countries (LMICs)are under-represented in reports on the burden of antimicrobial resistance. We aimed to quantify the clinical effect of carbapenem resistance on mortality and length of hospital stay among inpatients in LMICs with a bloodstream infection due to Enterobacteriaceae. Methods: The PANORAMA study was a multinational prospective cohort study at tertiary hospitals in Bangladesh, Colombia, Egypt, Ghana, India, Lebanon, Nepal, Nigeria, Pakistan, and Vietnam, recruiting consecutively diagnosed patients with carbapenem-susceptible Enterobacteriaceae (CSE)and carbapenem-resistant Entero-bacteriaceae (CRE)bloodstream infections. We excluded patients who had previously been enrolled in the study and those not treated with curative intent at the time of bloodstream infection onset. There were no age restrictions. Central laboratories in India and the UK did confirmatory testing and molecular characterisation, including strain typing. We applied proportional subdistribution hazard models with inverse probability weighting to estimate the effect of carbapenem resistance on probability of discharge alive and in-hospital death, and multistate modelling for excess length of stay in hospital. All patients were included in the analysis. Findings: Between Aug 1, 2014, and June 30, 2015, we recruited 297 patients from 16 sites in ten countries: 174 with CSE bloodstream infection and 123 with CRE bloodstream infection. Median age was 46 years (IQR 15–61). Crude mortality was 20% (35 of 174 patients)for patients with CSE bloodstream infection and 35% (43 of 123 patients)for patients with CRE bloodstream infection. Carbapenem resistance was associated with an increased length of hospital stay (3·7 days, 95% CI 0·3–6·9), increased probability of in-hospital mortality (adjusted subdistribution hazard ratio 1·75, 95% CI 1·04–2·94), and decreased probability of discharge alive (0·61, 0·45–0·83). Multilocus sequence typing showed various clades, with marginal overlap between strains in the CRE and CSE clades. Interpretation: Carbapenem resistance is associated with increased length of hospital stay and mortality in patients with bloodstream infections in LMICs. These data will inform global estimates of the burden of antimicrobial resistance and reinforce the need for better strategies to prevent, diagnose, and treat CRE infections in LMICs. Funding: bioMérieux.

Original languageEnglish
Pages (from-to)601-610
Number of pages10
JournalThe Lancet Infectious Diseases
Issue number6
Publication statusPublished - 1 Jun 2019

Cite this